|
1
|
Stupp R, Mason WP, van den Bent MJ, et al;
European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada
Clinical Trials Group. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lamborn KR, Yung WK, Chang SM, et al;
North American Brain Tumor Consortium. Progression-free survival:
an important end point in evaluating therapy for recurrent
high-grade gliomas. Neuro Oncol. 10:162–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wong ET, Hess KR, Gleason MJ, et al:
Outcomes and prognostic factors in recurrent glioma patients
enrolled onto phase II clinical trials. J Clin Oncol. 17:2572–2578.
1999.PubMed/NCBI
|
|
4
|
Arita N, Taneda M and Hayakawa T:
Leptomeningeal dissemination of malignant gliomas. Incidence,
diagnosis and outcome. Acta Neurochir (Wien). 126:84–92. 1994.
View Article : Google Scholar
|
|
5
|
Awad I, Bay JW and Rogers L:
Leptomeningeal metastasis from supratentorial malignant gliomas.
Neurosurgery. 19:247–251. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vertosick FT Jr and Selker RG: Brain stem
and spinal metastases of supratentorial glioblastoma multiforme: a
clinical series. Neurosurgery. 27:516–522. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Delattre JY, Walker RW and Rosenblum MK:
Leptomeningeal gliomatosis with spinal cord or cauda equina
compression: a complication of supratentorial gliomas in adults.
Acta Neurol Scand. 79:133–139. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nandipati S and Demopoulos A:
Leptomeningeal dissemination of anaplastic glioma: prolonged
survival in two patients treated with temozolomide. J Neurooncol.
105:663–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Narita Y: Drug review: Safety and efficacy
of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin
Oncol. 43:587–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Groves MD, DeGroot J, Tremont I, Forman A,
Kang S, Pei BL, et al: A pilot study of systemically administered
bevacizumab with neoplastic meningitis NM: imaging, clinical, CSF,
and biomarker outcomes. Neuro Oncol (OT-02). 13:iii85–iii91.
2011.
|
|
11
|
Fiorentino A, Caivano R, Chiumento C,
Cozzolino M and Fusco V: Radiotherapy and bevacizumab for
intramedullary and leptomenigeal metastatic glioblastoma: a case
report and review of the literature. Int J Neurosci. 122:691–694.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hübner F, Braun V and Richter HP: Case
reports of symptomatic metastases in four patients with primary
intracranial gliomas. Acta Neurochir (Wien). 143:25–29. 2001.
View Article : Google Scholar
|
|
13
|
Onda K, Tanaka R, Takahashi H, Takeda N
and Ikuta F: Cerebral glioblastoma with cerebrospinal fluid
dissemination: a clinicopathological study of 14 cases examined by
complete autopsy. Neurosurgery. 25:533–540. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chamberlain MC: Combined-modality
treatment of leptomeningeal gliomatosis. Neurosurgery. 52:324–330.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miller K, Wang M, Gralow J, et al:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang JC, Haworth L, Sherry RM, et al: A
randomized trial of bevacizumab, an anti-vascular endothelial
growth factor antibody, for metastatic renal cancer. N Engl J Med.
349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giantonio BJ, Catalano PJ, Meropol NJ, et
al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in
combination with oxaliplatin, fluorouracil, and leucovorin
(FOLFOX4) for previously treated metastatic colorectal cancer:
results from the Eastern Cooperative Oncology Group Study E3200. J
Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vincent A, Lesser G, Brown D, et al:
Prolonged regression of metastatic leptomeningeal breast cancer
that has failed conventional therapy: a case report and review of
the literature. J Breast Cancer. 16:122–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Braganca KC, Janjigian YY, Azzoli CG,
et al: Efficacy and safety of bevacizumab in active brain
metastases from non-small cell lung cancer. J Neurooncol.
100:443–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ku GY, Krol G and Ilson DH: Successful
treatment of leptomeningeal disease in colorectal cancer with a
regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol.
25:e14–e16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le Rhun E, Taillibert S and Chamberlain
MC: Carcinomatous meningitis: Leptomeningeal metastases in solid
tumors. Surg Neurol Int. 4:S265–S288. 2013.PubMed/NCBI
|
|
24
|
Mohan A and Ponnusankar S: Newer therapies
for the treatment of metastatic breast cancer: a clinical update.
Indian J Pharm Sci. 75:251–261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foubert F, Matysiak-Budnik T and Touchefeu
Y: Options for metastatic colorectal cancer beyond the second line
of treatment. Dig Liver Dis. 46:105–112. 2014. View Article : Google Scholar
|
|
26
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chamberlain MC and Johnston SK: Salvage
therapy with single agent bevacizumab for recurrent glioblastoma. J
Neurooncol. 96:259–269. 2010. View Article : Google Scholar
|
|
30
|
Wong ET, Gautam S, Malchow C, Lun M, Pan E
and Brem S: Bevacizumab for recurrent glioblastoma multiforme: a
meta-analysis. J Natl Compr Canc Netw. 9:403–407. 2011.PubMed/NCBI
|
